Identification

Name
Nilotinib
Accession Number
DB04868
Type
Small Molecule
Groups
Approved, Investigational
Description

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment. [Wikipedia]

Structure
Thumb
Synonyms
  • Nilotinibum
External IDs
AMN 107 / AMN-107 / AMN107
Product Ingredients
IngredientUNIICASInChI Key
Nilotinib hydrochloride monohydrate5JHU0N1R6K923288-90-8YCBPQSYLYYBPDW-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TasignaCapsule200 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis2008-09-30Not applicableCanada
TasignaCapsule200 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
TasignaCapsule50 mg/1OralNovartis2007-10-29Not applicableUs
TasignaCapsule200 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
TasignaCapsule150 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
TasignaCapsule150 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
TasignaCapsule200 mgOralNovartis Europharm Limited2007-11-19Not applicableEu
Categories
UNII
F41401512X
CAS number
641571-10-0
Weight
Average: 529.5158
Monoisotopic: 529.183792976
Chemical Formula
C28H22F3N7O
InChI Key
HHZIURLSWUIHRB-UHFFFAOYSA-N
InChI
InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)
IUPAC Name
4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide
SMILES
CC1=CN(C=N1)C1=CC(=CC(NC(=O)C2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)=C1)C(F)(F)F

Pharmacology

Indication

For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).

Associated Conditions
Pharmacodynamics

Nilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML).

Mechanism of action

Chronic myelogenous leukaemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein. Nilotinib fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib, over-riding resistance caused by mutations. The ability of AMN107 to inhibit TEL-platelet-derived growth factor receptor-beta (TEL-PDGFRbeta), which causes chronic myelomonocytic leukaemia, and FIP1-like-1-PDGFRalpha, which causes hypereosinophilic syndrome, suggests potential use of AMN107 for myeloproliferative diseases characterised by these kinase fusions (Stover et al, 2005; Weisberg et al, 2005). AMN107 also inhibits the c-Kit receptor kinase, including the D816V-mutated variant of KIT, at pharmacologically achievable concentrations, supporting potential utility in the treatment of mastocytosis, and gastrointestinal stromal tumours (Weisberg et al, 2005; von Bubnoff et al, 2005; Gleixner et al, 2006).

TargetActionsOrganism
ATyrosine-protein kinase ABL1
inhibitor
Human
UMast/stem cell growth factor receptor Kit
antagonist
Human
Absorption

Orally available

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

15 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nilotinib Inhibition of BCR-ABLDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
UDP-glucuronosyltransferase 1-1UGT1A1*28 or UGT1A 7/7Not Availableextra TA in promoterADR Directly StudiedPatients who carry this polymorphism in UGT1A1 are at a higer risk of developing hyperbilirubinemia when treated with nilotinib.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Nilotinib.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Nilotinib.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nilotinib.Experimental, Illicit
AbemaciclibThe metabolism of Abemaciclib can be decreased when combined with Nilotinib.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Nilotinib.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Nilotinib.Approved, Investigational
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Nilotinib.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Nilotinib.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nilotinib.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Nilotinib can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Nilotinib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Nilotinib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Nilotinib.Experimental
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Nilotinib.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Nilotinib.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nilotinib.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Nilotinib.Experimental, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Nilotinib.Approved, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Nilotinib.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Nilotinib.Approved
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Nilotinib.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Nilotinib.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Nilotinib.Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Nilotinib.Approved
AlmasilateThe serum concentration of Nilotinib can be decreased when it is combined with Almasilate.Approved, Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nilotinib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Nilotinib.Approved
AloglutamolThe serum concentration of Nilotinib can be decreased when it is combined with Aloglutamol.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Nilotinib.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Nilotinib.Approved
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Nilotinib.Approved, Withdrawn
AluminiumThe serum concentration of Nilotinib can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Nilotinib can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Nilotinib can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe serum concentration of Nilotinib can be decreased when it is combined with Aluminum hydroxide.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Nilotinib.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Nilotinib.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Nilotinib.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Nilotinib.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Nilotinib.Approved
AmiodaroneThe serum concentration of Nilotinib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Nilotinib.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Nilotinib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Nilotinib.Approved, Investigational
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Nilotinib.Approved, Investigational
AmoxapineAmoxapine may increase the QTc-prolonging activities of Nilotinib.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Nilotinib.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Nilotinib.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Nilotinib.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Nilotinib.Approved, Investigational, Withdrawn
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Nilotinib is combined with Anthrax immune globulin human.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Nilotinib.Approved, Investigational
ApalutamideThe serum concentration of Nilotinib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nilotinib.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ApremilastThe metabolism of Apremilast can be decreased when combined with Nilotinib.Approved, Investigational
AprepitantThe serum concentration of Nilotinib can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Nilotinib.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Nilotinib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Nilotinib.Approved, Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Nilotinib.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Nilotinib is combined with Artemether.Approved
AsenapineThe serum concentration of Nilotinib can be decreased when it is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Nilotinib.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Nilotinib.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Nilotinib can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Nilotinib.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Nilotinib is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Nilotinib.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Nilotinib.Approved, Investigational
AxitinibThe metabolism of Axitinib can be decreased when combined with Nilotinib.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Nilotinib.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Nilotinib.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Nilotinib is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Nilotinib is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Nilotinib.Investigational
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Nilotinib.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Nilotinib.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Nilotinib.Investigational
BedaquilineBedaquiline may increase the QTc-prolonging activities of Nilotinib.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Nilotinib.Investigational
BenidipineThe metabolism of Benidipine can be decreased when combined with Nilotinib.Approved, Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Nilotinib.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Nilotinib.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Nilotinib.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Nilotinib.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Nilotinib.Investigational
BetaxololThe metabolism of Betaxolol can be decreased when combined with Nilotinib.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Nilotinib.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Nilotinib.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Nilotinib.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Nilotinib.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Nilotinib.Approved, Experimental
Bismuth subcitrate potassiumThe serum concentration of Nilotinib can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Nilotinib can be decreased when it is combined with Bismuth subnitrate.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Nilotinib.Approved
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Nilotinib.Approved, Investigational
BoceprevirThe serum concentration of Nilotinib can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibBortezomib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Nilotinib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nilotinib.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nilotinib.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Nilotinib.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Nilotinib.Approved, Investigational
BrinzolamideThe metabolism of Brinzolamide can be decreased when combined with Nilotinib.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Nilotinib.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nilotinib.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Nilotinib.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Nilotinib.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Nilotinib.Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Nilotinib.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Nilotinib.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Nilotinib.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Nilotinib.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Nilotinib.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Nilotinib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nilotinib.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Nilotinib.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Nilotinib.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Nilotinib.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Nilotinib.Approved, Nutraceutical
Calcium CarbonateThe serum concentration of Nilotinib can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe serum concentration of Nilotinib can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Nilotinib.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Nilotinib.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Nilotinib.Approved
CarbamazepineThe serum concentration of Nilotinib can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Nilotinib.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Nilotinib.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Nilotinib.Approved, Investigational
CarteololThe metabolism of Carteolol can be decreased when combined with Nilotinib.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Nilotinib.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Nilotinib.Experimental
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Nilotinib.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Nilotinib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Nilotinib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nilotinib.Approved, Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Nilotinib.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Nilotinib.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
ChloroquineChloroquine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Nilotinib.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Nilotinib.Approved, Investigational
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Nilotinib.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Nilotinib.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Nilotinib.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nilotinib.Experimental
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Nilotinib.Approved, Investigational
CimetidineThe serum concentration of Nilotinib can be decreased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Nilotinib.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Nilotinib.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Cisapride is combined with Nilotinib.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Nilotinib.Approved
ClarithromycinThe serum concentration of Nilotinib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Nilotinib can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Nilotinib.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Nilotinib.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Nilotinib.Approved, Illicit
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Nilotinib.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Nilotinib.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Nilotinib.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Nilotinib.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Nilotinib.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Nilotinib.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Nilotinib.Approved, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Nilotinib is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Nilotinib.Approved, Illicit
ClotrimazoleThe metabolism of Nilotinib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Clozapine.Approved
CobicistatThe serum concentration of Nilotinib can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nilotinib.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Nilotinib.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Nilotinib.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nilotinib.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nilotinib.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Nilotinib.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Nilotinib.Approved, Investigational
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Nilotinib.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Nilotinib is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Nilotinib.Approved
CurcuminThe serum concentration of Nilotinib can be increased when it is combined with Curcumin.Approved, Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
CyclosporineThe metabolism of Nilotinib can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Nilotinib.Experimental
CytarabineThe metabolism of Cytarabine can be decreased when combined with Nilotinib.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Nilotinib.Approved
DabrafenibThe serum concentration of Nilotinib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe metabolism of Daclatasvir can be decreased when combined with Nilotinib.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Nilotinib.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Nilotinib.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Nilotinib.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Nilotinib.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Nilotinib.Approved, Investigational
DarunavirThe serum concentration of Nilotinib can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Nilotinib.Approved
DasatinibThe serum concentration of Nilotinib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Nilotinib.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Nilotinib.Approved, Investigational
DeferasiroxThe serum concentration of Nilotinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Nilotinib.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Nilotinib.Approved
DelamanidThe metabolism of Delamanid can be decreased when combined with Nilotinib.Approved, Investigational
DelavirdineThe metabolism of Nilotinib can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Nilotinib.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Nilotinib.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Nilotinib.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Nilotinib.Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Nilotinib.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Nilotinib.Approved, Investigational
DexamethasoneThe serum concentration of Nilotinib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Nilotinib.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Nilotinib.Approved, Illicit, Investigational, Withdrawn
DexlansoprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Dexlansoprazole.Approved, Investigational
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Nilotinib.Approved, Investigational
DexrabeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Dexrabeprazole.Experimental
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Nilotinib.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Nilotinib.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Nilotinib.Approved, Illicit, Investigational, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Nilotinib.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Nilotinib.Approved, Vet Approved
DienogestThe metabolism of Dienogest can be decreased when combined with Nilotinib.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Nilotinib.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Nilotinib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nilotinib.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Nilotinib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Nilotinib.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nilotinib.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nilotinib.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nilotinib.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nilotinib.Approved, Investigational
DiltiazemThe metabolism of Nilotinib can be decreased when combined with Diltiazem.Approved, Investigational
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Nilotinib.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Nilotinib.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilotinib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Nilotinib.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nilotinib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Nilotinib.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Nilotinib.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Nilotinib.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Nilotinib.Approved
DoxepinThe serum concentration of Nilotinib can be decreased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nilotinib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Nilotinib.Approved, Investigational
DoxycyclineThe metabolism of Nilotinib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Nilotinib.Approved, Illicit
DronedaroneThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Nilotinib.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nilotinib.Approved, Investigational
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Nilotinib.Approved
DutasterideThe metabolism of Dutasteride can be decreased when combined with Nilotinib.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nilotinib.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Nilotinib.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Nilotinib.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nilotinib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Nilotinib.Approved
EltrombopagThe serum concentration of Nilotinib can be increased when it is combined with Eltrombopag.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Nilotinib.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Nilotinib.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Nilotinib.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Nilotinib.Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Nilotinib.Experimental
EnzalutamideThe serum concentration of Nilotinib can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Nilotinib can be decreased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Nilotinib.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Nilotinib.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Nilotinib.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nilotinib.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Nilotinib.Approved
EribulinEribulin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Nilotinib.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Nilotinib.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Nilotinib.Investigational
EsomeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe metabolism of Estazolam can be decreased when combined with Nilotinib.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Nilotinib.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Nilotinib.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Nilotinib.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Nilotinib.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Nilotinib.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Nilotinib.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Nilotinib.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Nilotinib.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Nilotinib.Approved, Illicit
EtizolamThe metabolism of Etizolam can be decreased when combined with Nilotinib.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Nilotinib.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Nilotinib.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Nilotinib.Approved, Investigational
EtravirineThe metabolism of Etravirine can be decreased when combined with Nilotinib.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nilotinib.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Nilotinib.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Nilotinib.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Nilotinib.Approved, Investigational
FamotidineThe serum concentration of Nilotinib can be decreased when it is combined with Famotidine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Nilotinib.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Nilotinib.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Nilotinib.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Nilotinib.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nilotinib.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Nilotinib.Approved
FingolimodNilotinib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Nilotinib.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Nilotinib is combined with Flibanserin.Approved, Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Nilotinib.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Nilotinib.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Nilotinib.Approved, Illicit
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Nilotinib.Approved, Investigational
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Nilotinib.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Nilotinib.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Nilotinib.Approved, Investigational, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Nilotinib.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Nilotinib.Approved, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Nilotinib.Approved
Fluticasone propionateThe metabolism of Fluticasone propionate can be decreased when combined with Nilotinib.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Nilotinib.Approved
FluvoxamineThe metabolism of Nilotinib can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
FosamprenavirThe metabolism of Nilotinib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nilotinib can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Nilotinib.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Nilotinib.Approved
FosphenytoinThe serum concentration of Nilotinib can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Nilotinib.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Nilotinib.Approved, Investigational
Fusidic AcidThe serum concentration of Nilotinib can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Nilotinib is combined with G17DT.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Nilotinib.Approved
GefitinibThe metabolism of Gefitinib can be decreased when combined with Nilotinib.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Nilotinib.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
GI-5005The risk or severity of adverse effects can be increased when Nilotinib is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Nilotinib.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Nilotinib.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Nilotinib.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Nilotinib.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Nilotinib.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Nilotinib.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Nilotinib.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Nilotinib.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Nilotinib.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Nilotinib.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Nilotinib.Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Nilotinib.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Nilotinib.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Nilotinib.Approved, Vet Approved
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Nilotinib is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Nilotinib.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Nilotinib.Approved, Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Nilotinib.Approved
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Nilotinib is combined with Human rabies virus immune globulin.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Nilotinib.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Nilotinib.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Nilotinib.Approved, Illicit
HydrotalciteThe serum concentration of Nilotinib can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nilotinib.Approved, Investigational
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Nilotinib.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Nilotinib.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Nilotinib.Approved
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Nilotinib.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Nilotinib.Approved, Investigational
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Nilotinib.Approved
IdelalisibThe serum concentration of Nilotinib can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nilotinib resulting in a loss in efficacy.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Nilotinib is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nilotinib.Approved
ImidafenacinThe metabolism of Imidafenacin can be decreased when combined with Nilotinib.Approved, Investigational
ImipramineImipramine may increase the QTc-prolonging activities of Nilotinib.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Nilotinib.Approved, Investigational
IndacaterolIndacaterol may increase the QTc-prolonging activities of Nilotinib.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Nilotinib.Approved
IndinavirThe serum concentration of Nilotinib can be increased when it is combined with Indinavir.Approved
INGN 201The risk or severity of adverse effects can be increased when Nilotinib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Nilotinib is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nilotinib.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Nilotinib.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nilotinib.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Nilotinib.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Nilotinib.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nilotinib.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nilotinib.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Nilotinib.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium bromide can be decreased when combined with Nilotinib.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Nilotinib.Approved, Investigational
IrinotecanThe serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Nilotinib.Approved, Investigational
IsavuconazoleThe serum concentration of Nilotinib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Isavuconazonium can be decreased when combined with Nilotinib.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Nilotinib.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nilotinib.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
ItraconazoleThe serum concentration of Nilotinib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Nilotinib.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Nilotinib.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
IxabepiloneThe metabolism of Ixabepilone can be decreased when combined with Nilotinib.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Nilotinib.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Nilotinib is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Nilotinib.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Nilotinib.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Nilotinib.Approved, Investigational
KetoconazoleThe serum concentration of Nilotinib can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Nilotinib.Approved
LacidipineThe metabolism of Lacidipine can be decreased when combined with Nilotinib.Approved, Investigational
LafutidineThe serum concentration of Nilotinib can be decreased when it is combined with Lafutidine.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Nilotinib.Experimental
LansoprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Nilotinib.Investigational
LavoltidineThe serum concentration of Nilotinib can be decreased when it is combined with Lavoltidine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nilotinib.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Nilotinib is combined with Leflunomide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Nilotinib.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Nilotinib.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Nilotinib.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Nilotinib.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Nilotinib.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Nilotinib.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Nilotinib.Approved, Investigational
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Nilotinib.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Nilotinib.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Nilotinib.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Nilotinib.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Nilotinib.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Nilotinib.Approved
LipegfilgrastimNilotinib may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Nilotinib.Approved
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Nilotinib.Approved, Investigational
Lithium cationLithium may increase the QTc-prolonging activities of Nilotinib.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Nilotinib.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Nilotinib.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Nilotinib.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Nilotinib.Approved
LopinavirThe serum concentration of Nilotinib can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Nilotinib.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Nilotinib.Approved
LorpiprazoleThe serum concentration of Nilotinib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Nilotinib.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nilotinib.Approved, Investigational
LuliconazoleThe serum concentration of Nilotinib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nilotinib can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Nilotinib is combined with Lumefantrine.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Nilotinib.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nilotinib.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Nilotinib.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Nilotinib.Approved
MagaldrateThe serum concentration of Nilotinib can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium silicate.Approved
Magnesium TrisilicateThe serum concentration of Nilotinib can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
MaravirocThe metabolism of Maraviroc can be decreased when combined with Nilotinib.Approved, Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Nilotinib.Approved, Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Nilotinib.Experimental, Investigational
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be decreased when combined with Nilotinib.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Nilotinib.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Nilotinib.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Nilotinib.Investigational, Withdrawn
MequitazineThe metabolism of Mequitazine can be decreased when combined with Nilotinib.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Nilotinib.Approved, Investigational
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Nilotinib.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Nilotinib.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Nilotinib.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Nilotinib.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Nilotinib.Approved, Illicit
MethanthelineThe serum concentration of Nilotinib can be decreased when it is combined with Methantheline.Approved, Investigational
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Nilotinib.Illicit, Withdrawn
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Nilotinib.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Nilotinib.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Nilotinib.Approved, Investigational
MethylprednisoloneThe metabolism of Methylprednisolone can be decreased when combined with Nilotinib.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Nilotinib.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Nilotinib.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Nilotinib.Approved
MetiamideThe serum concentration of Nilotinib can be decreased when it is combined with Metiamide.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Nilotinib.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Nilotinib.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Nilotinib.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Nilotinib.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Nilotinib.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Nilotinib.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Nilotinib.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Nilotinib.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Nilotinib.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Nilotinib.Approved, Investigational
MifepristoneNilotinib may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Nilotinib.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Nilotinib.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Nilotinib.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Nilotinib.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Nilotinib.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Nilotinib.Approved, Investigational
MitotaneThe serum concentration of Nilotinib can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Nilotinib.Approved, Investigational
ModafinilThe metabolism of Modafinil can be decreased when combined with Nilotinib.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Nilotinib.Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Nilotinib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Nilotinib.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be decreased when combined with Nilotinib.Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Nilotinib.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Nilotinib.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nilotinib.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Nilotinib.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Nilotinib.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Nilotinib.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Nilotinib.Approved, Investigational
NefazodoneThe serum concentration of Nilotinib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nilotinib can be increased when it is combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Nilotinib.Approved, Investigational
NetupitantThe serum concentration of Nilotinib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Nilotinib can be decreased when it is combined with Nevirapine.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Nilotinib.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Nilotinib.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Nilotinib.Approved
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nilotinib.Approved
NiperotidineThe serum concentration of Nilotinib can be decreased when it is combined with Niperotidine.Experimental, Investigational
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Nilotinib.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Nilotinib.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Nilotinib.Approved, Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
NizatidineThe serum concentration of Nilotinib can be decreased when it is combined with Nizatidine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Nilotinib.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Nilotinib.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Nilotinib.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Nilotinib.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Nilotinib.Approved, Investigational
OctreotideOctreotide may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Nilotinib.Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Nilotinib.Approved
OlanzapineThe serum concentration of Nilotinib can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Nilotinib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Nilotinib.Experimental, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Nilotinib.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Nilotinib.Approved
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Nilotinib.Approved, Investigational
OmeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Nilotinib.Approved
OpiumThe metabolism of Opium can be decreased when combined with Nilotinib.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Nilotinib.Approved
OsimertinibThe serum concentration of Nilotinib can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Nilotinib.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Nilotinib.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Nilotinib.Approved
OxybutyninThe metabolism of Oxybutynin can be decreased when combined with Nilotinib.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Nilotinib is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nilotinib.Approved, Vet Approved
PalbociclibThe serum concentration of Nilotinib can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Nilotinib.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Nilotinib.Approved, Investigational
PanobinostatPanobinostat may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
PantoprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Nilotinib.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Nilotinib.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Nilotinib.Approved
ParicalcitolThe metabolism of Paricalcitol can be decreased when combined with Nilotinib.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Nilotinib.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Nilotinib.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nilotinib.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
PentobarbitalThe serum concentration of Nilotinib can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Nilotinib.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Nilotinib.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Nilotinib.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Nilotinib.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Nilotinib.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Nilotinib.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Nilotinib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Nilotinib.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Nilotinib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Nilotinib.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Nilotinib can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Nilotinib.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be decreased when combined with Nilotinib.Approved, Investigational
PhenytoinThe serum concentration of Nilotinib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Nilotinib.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nilotinib.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Nilotinib.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Nilotinib.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Nilotinib.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Nilotinib.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Nilotinib.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Nilotinib.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Nilotinib.Approved, Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Nilotinib.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nilotinib.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Nilotinib.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Nilotinib.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Nilotinib.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Nilotinib.Approved, Investigational
PosaconazoleThe serum concentration of Nilotinib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Nilotinib.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Nilotinib.Approved, Investigational, Nutraceutical
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Nilotinib.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nilotinib.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Nilotinib.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Nilotinib.Approved, Vet Approved
PrednisoneThe metabolism of Prednisone can be decreased when combined with Nilotinib.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Nilotinib.Approved
PrimidoneThe serum concentration of Nilotinib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Nilotinib.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Nilotinib.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Nilotinib.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Nilotinib.Approved
PromazinePromazine may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
PromethazineThe serum concentration of Nilotinib can be decreased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Nilotinib can be increased when it is combined with Propafenone.Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Nilotinib.Approved, Investigational
PropofolPropofol may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Nilotinib.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Nilotinib.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Nilotinib.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nilotinib.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Nilotinib.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Nilotinib.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Nilotinib.Approved, Illicit
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Nilotinib.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Nilotinib.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Nilotinib.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Nilotinib.Approved
RabeprazoleThe serum concentration of Nilotinib can be decreased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nilotinib.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Nilotinib.Approved, Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Nilotinib.Approved, Investigational
RanitidineThe serum concentration of Nilotinib can be decreased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nilotinib.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Nilotinib.Approved, Investigational
RegorafenibThe metabolism of Regorafenib can be decreased when combined with Nilotinib.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Nilotinib.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Nilotinib.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Nilotinib.Investigational
RetapamulinThe metabolism of Retapamulin can be decreased when combined with Nilotinib.Approved
RifabutinThe serum concentration of Nilotinib can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Nilotinib can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nilotinib can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Nilotinib.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nilotinib.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Nilotinib.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rindopepimut.Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Nilotinib.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Nilotinib.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Nilotinib.Approved
RolapitantThe serum concentration of Nilotinib can be increased when it is combined with Rolapitant.Approved, Investigational
RomidepsinThe metabolism of Romidepsin can be decreased when combined with Nilotinib.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Nilotinib.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Nilotinib.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Nilotinib.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Nilotinib.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rotavirus Vaccine.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Nilotinib.Approved
Roxatidine acetateThe serum concentration of Nilotinib can be decreased when it is combined with Roxatidine acetate.Approved, Investigational
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe metabolism of Rucaparib can be decreased when combined with Nilotinib.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Nilotinib.Approved
RuxolitinibThe metabolism of Ruxolitinib can be decreased when combined with Nilotinib.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Nilotinib.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Nilotinib.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Nilotinib is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Nilotinib is combined with Salmonella typhi ty21a live antigen.Approved
SaquinavirThe serum concentration of Nilotinib can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Nilotinib can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Nilotinib.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Nilotinib.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Nilotinib.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Nilotinib.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Nilotinib.Approved, Illicit, Investigational, Withdrawn
SildenafilThe metabolism of Nilotinib can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nilotinib.Approved
SiltuximabThe serum concentration of Nilotinib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nilotinib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nilotinib.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nilotinib.Approved, Investigational
SirolimusThe metabolism of Sirolimus can be decreased when combined with Nilotinib.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Nilotinib.Approved, Investigational
Sodium bicarbonateThe serum concentration of Nilotinib can be decreased when it is combined with Sodium bicarbonate.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Nilotinib.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Nilotinib.Approved, Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Nilotinib.Investigational
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Nilotinib.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Nilotinib.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Nilotinib.Approved
SRP 299The risk or severity of adverse effects can be increased when Nilotinib is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Nilotinib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Nilotinib can be increased when it is combined with Stiripentol.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Nilotinib.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Nilotinib.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Nilotinib.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Nilotinib.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Nilotinib.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nilotinib.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nilotinib.Approved
TacrolimusTacrolimus may increase the immunosuppressive activities of Nilotinib.Approved, Investigational
TadalafilThe metabolism of Tadalafil can be decreased when combined with Nilotinib.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Nilotinib resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Nilotinib.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Nilotinib.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Nilotinib.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nilotinib.Experimental
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Nilotinib.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Nilotinib is combined with Tecemotide.Investigational
TegaserodThe metabolism of Tegaserod can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Nilotinib can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Nilotinib.Approved
TelithromycinThe serum concentration of Nilotinib can be increased when it is combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Nilotinib.Approved, Investigational
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Nilotinib.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Nilotinib.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Nilotinib.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Nilotinib.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Nilotinib.Experimental
TeriflunomideThe serum concentration of Nilotinib can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Nilotinib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Nilotinib.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Nilotinib.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Nilotinib.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Nilotinib.Approved, Investigational
TetrabenazineThe risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Nilotinib.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Nilotinib.Approved, Vet Approved
TezacaftorThe metabolism of Tezacaftor can be decreased when combined with Nilotinib.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Nilotinib is combined with TG4010.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Nilotinib.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Nilotinib.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Nilotinib.Approved, Investigational
ThiothixeneThiothixene may increase the QTc-prolonging activities of Nilotinib.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Nilotinib.Approved, Investigational
TicagrelorThe metabolism of Ticagrelor can be decreased when combined with Nilotinib.Approved
TiclopidineThe metabolism of Nilotinib can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Nilotinib.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Nilotinib.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Nilotinib.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Nilotinib.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TocilizumabThe serum concentration of Nilotinib can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Nilotinib.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Nilotinib.Approved, Investigational
TofacitinibNilotinib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Nilotinib.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Nilotinib.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nilotinib.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nilotinib.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Nilotinib.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Nilotinib.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Nilotinib.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Nilotinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Nilotinib.Approved, Investigational
Trastuzumab emtansineThe metabolism of Trastuzumab emtansine can be decreased when combined with Nilotinib.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Nilotinib.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Nilotinib.Approved, Vet Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Nilotinib.Approved, Investigational
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Nilotinib.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Nilotinib.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Nilotinib.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Nilotinib.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Nilotinib.Approved
TromethamineThe serum concentration of Nilotinib can be decreased when it is combined with Tromethamine.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Typhoid Vaccine.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Nilotinib.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Nilotinib.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Nilotinib.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Nilotinib.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
VandetanibThe risk or severity of QTc prolongation can be increased when Nilotinib is combined with Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Nilotinib.Investigational
VardenafilVardenafil may increase the QTc-prolonging activities of Nilotinib.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Nilotinib is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Nilotinib.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nilotinib.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Nilotinib.Approved, Investigational
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Nilotinib.Approved
VerapamilThe metabolism of Nilotinib can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Nilotinib.Approved, Investigational
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Nilotinib.Investigational
VilanterolVilanterol may increase the QTc-prolonging activities of Nilotinib.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Nilotinib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nilotinib.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Nilotinib.Approved
VincristineThe metabolism of Vincristine can be decreased when combined with Nilotinib.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Nilotinib.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Nilotinib.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Nilotinib.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Nilotinib.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Nilotinib.Approved, Investigational
VoriconazoleThe serum concentration of Nilotinib can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Nilotinib.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Nilotinib.Approved, Investigational
WarfarinThe metabolism of Warfarin can be decreased when combined with Nilotinib.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Nilotinib is combined with Yellow Fever Vaccine.Approved, Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Nilotinib.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Nilotinib.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Nilotinib.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Nilotinib.Approved, Illicit, Investigational
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Nilotinib.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Nilotinib.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Nilotinib.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Nilotinib.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Nilotinib.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Nilotinib.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Nilotinib.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Nilotinib.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Yanling WANG, Jie LI, Vinod Kumar KANSAL, Jirang ZHU, Revital LIFSHITZ-LIRON, Dhirenkumar N. MISTRY, Sanjay L. VASOYA, Sundaraselvan ARIYAMUTHU, Gideon PILARSKI, Xungui HE, "NILOTINIB INTERMEDIATES AND PREPARATION THEREOF." U.S. Patent US20100016590, issued January 21, 2010.

US20100016590
General References
  1. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. [PubMed:16775235]
  2. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. [PubMed:17929114]
  3. Breccia M, Cannella L, Nanni M, Stefanizzi C, Alimena G: Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta Haematol. 2007;118(3):162-4. Epub 2007 Sep 20. [PubMed:17890849]
  4. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22. [PubMed:17715389]
  5. Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H: Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs. 2007 Jul;10(7):468-79. [PubMed:17642017]
External Links
Human Metabolome Database
HMDB0015595
PubChem Compound
644241
PubChem Substance
99443226
ChemSpider
559260
BindingDB
50237710
ChEBI
52172
ChEMBL
CHEMBL255863
PharmGKB
PA165958345
HET
NIL
Wikipedia
Nilotinib
ATC Codes
L01XE08 — Nilotinib
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
PDB Entries
3cs9 / 3gp0 / 5mo4
MSDS
Download (68.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentNeurofibromas / Neurofibromatosis / NF11
0Not Yet RecruitingTreatmentChronic Myeloid Leukemia (CML)1
0WithdrawnOtherMalignant Neoplasm of Colon1
1Active Not RecruitingTreatmentChordomas1
1Active Not RecruitingTreatmentChronic Phase Chronic Myeloid Leukemia1
1CompletedNot AvailableChronic Myeloid Leukemia (CML)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML)1
1CompletedTreatmentChronic Graft Versus Host Disease1
1CompletedTreatmentChronic Myeloid Leukemia (CML)1
1CompletedTreatmentDiffuse Lewy Body Disease / Parkinson's Disease (PD) / Parkinson's Disease Dementia (PDD)1
1CompletedTreatmentGastrointestinal Stromal Tumors2
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentPhiladelphia Chromosome Positive Chronic Myelogenous Leukemia1
1RecruitingTreatmentChronic Myelogenous Leukemia (CML) / Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia1
1RecruitingTreatmentColorectal Cancers / Head and Neck Carcinoma1
1RecruitingTreatmentRecurrent Low-grade Gliomas / Refractory Low-grade Gliomas1
1RecruitingTreatmentTumors, Solid1
1RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
1TerminatedTreatmentLeukemias1
1Unknown StatusTreatmentBone Marrow Transplant Failure / Lymphoma, T-Cell, Peripheral / Non-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentChronic Myeloid Leukemia (CML)1
1, 2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Relapsing Chronic Myelogenous Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myelogenous Leukemia (CML)1
1, 2CompletedTreatmentAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) / Chronic Myelogenous Leukemia (CML)1
1, 2CompletedTreatmentAcute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) / Chronic Myelogenous Leukemia (CML) / Hypereosinophilic Syndromes / Systemic Mastocytosis1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentAccelerated phase chronic myologenic leukemia / Blastic Phase Chronic Myeloid Leukemia / Chronic Phase Chronic Myeloid Leukemia / Philadelphia Positive Acute Lymphoblastic Leukemia / Resistant to Tyrosine Kinase Inhibitor Therapy1
1, 2RecruitingTreatmentChronic Myeloid Leukemia (CML)1
1, 2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma1
1, 2TerminatedTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Blastic Phase / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Chronic Phase Chronic Myelogenous Leukemia / Chronic Phase of Disease / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Disease / Relapsing Chronic Myelogenous Leukemia1
2Active Not RecruitingTreatmentBCR-ABL Positive / Bone Marrow Diseases / Dasatinib / Enzyme Inhibitor / Hematologic Diseases / Imatinib / Leukemia, Mylegenous, Accelerated / Leukemia, Mylegenous, Chronic / Leukemia, Myleiod / Leukemias / Myeloproliferative Disorders / Neoplastic Processes / Pediatric Leukemia / Protein Kinase Inhibitors1
2Active Not RecruitingTreatmentCML1
2Active Not RecruitingTreatmentChronic Myelogenous Leukemia (CML)1
2Active Not RecruitingTreatmentChronic Myeloid Leukemia (CML)3
2Active Not RecruitingTreatmentDiffuse-type Giant Cell Tumor / Synovitis, Pigmented Villonodular / Tenosynovial Giant Cell Tumor1
2Active Not RecruitingTreatmentGastrointestinal Stromal Tumors1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentLeukemia, Myelogenous, Chronic1
2Active Not RecruitingTreatmentLeukemia, Myeloid, Chronic-Phase1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentParkinson's Disease (PD) / Parkinsons Disease With Dementia1
2Active Not RecruitingTreatmentPhiladelphia Chromsome Positive Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentTransplantation, Stem Cell / Treatments1
2Active Not RecruitingTreatmentUntreated Adult Acute Myeloid Leukemia1
2CompletedPreventionMelanoma1
2CompletedTreatmentAcral Lentiginous Malignant Melanoma / Mucosal Lentiginous Melanoma1
2CompletedTreatmentAcral Melanoma / Melanoma / Mucosal Lentiginous Melanoma1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myeloid Leukemia (CML) / Transplantation, Stem Cell1
2CompletedTreatmentGastrointestinal Stromal Tumors2
2CompletedTreatmentGastrointestinal Stromal Tumors / Gastrointestinal Stromal Tumors (GISTs)1
2CompletedTreatmentLeukemias2
2CompletedTreatmentMetastatic Melanoma With KIT Aberration1
2CompletedTreatmentSclerosis, Progressive Systemic1
2CompletedTreatmentSynovitis, Pigmented Villonodular1
2Not Yet RecruitingTreatmentChronic Myelogenous Leukemia (CML) / CML / Hematologic Diseases / Leukemia, Myeloid Chronic1
2Not Yet RecruitingTreatmentChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Minimal Residual Disease1
2RecruitingBasic ScienceChronic Myeloid Leukemia (CML)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentCancers / Neoplasia / Neoplasms / Tumors1
2RecruitingTreatmentChronic Myelogenous Leukemia (CML) / Chronic Myeloid Leukemia (CML) / Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemias1
2RecruitingTreatmentChronic Myeloid Leukemia (CML)1
2RecruitingTreatmentChronic Myeloid Leukemia in Myeloid Blast Crisis / Untreated Adult Acute Myeloid Leukemia1
2RecruitingTreatmentGliomas1
2RecruitingTreatmentLeukemia, Myelogenous, Chronic, BCR-ABL Positive1
2RecruitingTreatmentMalignant Solid Neoplasms1
2RecruitingTreatmentRecurrent Low-grade Gliomas / Refractory Low-grade Gliomas1
2TerminatedTreatmentGIST / Metastatic Disease1
2TerminatedTreatmentGastrointestinal Stromal Tumors1
2TerminatedTreatmentGrowing Vestibular Schwannomas1
2TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
2Unknown StatusNot AvailableChronic Myeloid Leukemia (CML)1
2Unknown StatusPreventionPatients Who Have Received Allo-HSCT1
2Unknown StatusTreatmentAmplification / Malignant Skin Melanoma T0 / Stage III Melanoma / Stage IV Melanoma1
2Unknown StatusTreatmentChronic Myeloid Leukemia (CML)1
2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Blastic Phase Chronic Myelogenous Leukemia / Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2WithdrawnTreatmentGastrointestinal Cancers1
2, 3CompletedTreatmentLeukemia,Myeloid, Chronic1
3Active Not RecruitingDiagnosticChronic Myeloid Leukemia (CML)1
3Active Not RecruitingTreatmentChronic Myeloid Leukemia (CML)1
3Active Not RecruitingTreatmentChronic Phase Chronic Myeloid Leukemia1
3Active Not RecruitingTreatmentMyelogenous Leukemia, Chronic1
3Approved for MarketingNot AvailableChronic Myeloid Leukemia (CML)1
3CompletedTreatmentChronic Myelogenous Leukemia (CML)2
3CompletedTreatmentChronic Myeloid Leukemia (CML)3
3CompletedTreatmentGastrointestinal Stromal Tumors2
3CompletedTreatmentGastrointestinal Stromal Tumors (GISTs)1
3CompletedTreatmentLeukemia, Myeloid, Chronic, BCR-ABL Positive1
3CompletedTreatmentLeukemias1
3CompletedTreatmentPhiladelphia Positive (Ph+) Chronic Myeloid Leukemia1
3No Longer AvailableNot AvailableChronic Myelogenous Leukemia (CML)1
3No Longer AvailableNot AvailableChronic Myeloid Leukemia (CML)1
3RecruitingTreatmentChronic Myeloid Leukemia (CML)2
3RecruitingTreatmentChronic Myeloid Leukemia - Chronic Phase1
3RecruitingTreatmentLeukemia, Myeloid, Ph1-Positive1
3RecruitingTreatmentMyelogenous Leukemia, Chronic1
3RecruitingTreatmentPhiladelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia1
3SuspendedTreatmentChronic Myeloid Leukemia (CML)1
3TerminatedTreatmentGastrointestinal Stromal Tumors1
3TerminatedTreatmentMyelogenous Leukemia1
3TerminatedTreatmentPhilidelphia Positive Chronic Myeloid Leukaemia1
3Unknown StatusTreatmentChronic Myeloid Leukemia (CML)1
4Active Not RecruitingTreatmentGastrointestinal Stromal Tumors1
4CompletedTreatmentCML / Imatinib Intolerant / Imatinib Resistant / Nilotinib1
4CompletedTreatmentChronic Myelogenous Leukemia (CML)2
4CompletedTreatmentChronic Myelogenous Leukemia - Chronic Phase1
4CompletedTreatmentChronic Myelogenous Leukemia in Chronic Phase1
4CompletedTreatmentChronic Myelogenous Leukemia in Chronic Phase / Philadelphia Chromosome Positive1
4CompletedTreatmentChronic Myeloid Leukemia (CML)1
4CompletedTreatmentChronic Myeloid Leukemia, Chronic Phase1
4CompletedTreatmentMyeloid Leukemias1
4Not Yet RecruitingTreatmentChronic Myeloid Leukemia (CML)1
4RecruitingTreatmentChronic Myeloid Leukemia (CML)1
4RecruitingTreatmentChronyc Myeloid Leukemia1
4RecruitingTreatmentGIST and CML1
4TerminatedTreatmentChronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels / CML / Philadelphia Chromosome Positive (Ph+)1
4TerminatedTreatmentChronic Myelocytic Leukemia1
4WithdrawnTreatmentChronic Myeloid Leukemia (CML)1
Not AvailableCompletedNot AvailableAll Indications for Glivec/Gleevec and Tasigna1
Not AvailableCompletedNot AvailableChronic Myeloid Leukemia (CML)1
Not AvailableCompletedNot AvailableGastrointestinal Stromal Tumors1
Not AvailableRecruitingNot AvailableLeukemia, Lymphoblastic, Acute1
Not AvailableRecruitingTreatmentChronic Myelogenous Leukemia (CML)1
Not AvailableUnknown StatusNot AvailableChronic Myeloid Leukemia (CML)1
Not AvailableWithdrawnNot AvailableLeukemia, Myelogenous, Chronic, BCR-ABL Positive1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral150 mg/1
CapsuleOral150 mg
CapsuleOral200 mg
CapsuleOral200 mg/1
CapsuleOral50 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2491632No2009-11-102023-07-04Canada
US7169791Yes2004-01-042024-01-04Us
US8389537Yes2007-01-182027-01-18Us
US8415363Yes2007-01-182027-01-18Us
US8293756Yes2008-03-252028-03-25Us
US8501760Yes2007-01-182027-01-18Us
US8163904Yes2009-02-232029-02-23Us
US9061029Yes2012-10-072032-10-07Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00201 mg/mLALOGPS
logP4.51ALOGPS
logP4.41ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)11.86ChemAxon
pKa (Strongest Basic)6.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area97.62 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity152.85 m3·mol-1ChemAxon
Polarizability52.35 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9066
Caco-2 permeable-0.5792
P-glycoprotein substrateNon-substrate0.6879
P-glycoprotein inhibitor IInhibitor0.556
P-glycoprotein inhibitor IIInhibitor0.6002
Renal organic cation transporterNon-inhibitor0.8253
CYP450 2C9 substrateNon-substrate0.8178
CYP450 2D6 substrateNon-substrate0.8547
CYP450 3A4 substrateSubstrate0.5552
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.5739
CYP450 2D6 inhibitorNon-inhibitor0.8275
CYP450 2C19 inhibitorInhibitor0.5554
CYP450 3A4 inhibitorInhibitor0.6784
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7862
Ames testNon AMES toxic0.5204
CarcinogenicityNon-carcinogens0.8175
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6343 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9961
hERG inhibition (predictor II)Inhibitor0.8458
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0000090000-c81d93ae83b54aaca2f4
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-0000090000-2a5b68b4c129b14bb357
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090010000-4d81b7c6e95b1601807c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0290000000-5cdcf0a130834a5ce0fa
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-006x-1980000000-fe1aac1a4cf8b0cf243f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0089-4920000000-41fd6570440f9acb13a2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-9300000000-3dde52b181ab459e7373
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-9000000000-2fbed5a3e77fb33d74f6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0gc1-9000000000-8d60ba6c0beff21b5ceb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0000090000-ad94cdcfe3b41c7e6e1c
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-053i-0095050000-60d1fbdd2ffcd3cc7cb3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-0091000000-0b24555ab7c56e04ca80
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-08fr-0090000000-dac0910c08fc1e3b20b1
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0190000000-5cc32e0bf9ad1cbe4ae8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0390000000-7834bc808d80c86e0918
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4l-3890000000-c8db809bdbc2f49eb4db
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a6v-6940000000-2febde67f881b42dd11e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0h0a-9720000000-5868b8d3e3c7531fdfcd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0181090000-fac2f8f712c3e67b317e

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Benzanilides
Alternative Parents
Pyridinylpyrimidines / Phenylimidazoles / Trifluoromethylbenzenes / Aminobenzoic acids and derivatives / p-Toluamides / Benzamides / Aniline and substituted anilines / Benzoyl derivatives / Aminopyrimidines and derivatives / Pyridines and derivatives
show 12 more
Substituents
Benzanilide / Pyridinylpyrimidine / 1-phenylimidazole / Trifluoromethylbenzene / Aminobenzoic acid or derivatives / P-toluamide / Toluamide / Benzamide / Benzoic acid or derivatives / Benzoyl
show 29 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, pyrimidines, secondary amino compound, pyridines, carboxamide, (trifluoromethyl)benzenes (CHEBI:52172)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Syntaxin binding
Specific Function
Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility a...
Gene Name
ABL1
Uniprot ID
P00519
Uniprot Name
Tyrosine-protein kinase ABL1
Molecular Weight
122871.435 Da
References
  1. Maekawa T, Ashihara E, Kimura S: The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol. 2007 Oct;12(5):327-40. Epub 2007 Oct 22. [PubMed:17929114]
  2. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6. Epub 2007 Aug 22. [PubMed:17715389]
  3. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006 Jun 19;94(12):1765-9. Epub 2006 May 23. [PubMed:16721371]
  4. Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F: Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther. 2009 Sep 21;3:89-101. [PubMed:19920925]
  5. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M: Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. [PubMed:19822896]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Transmembrane receptor protein tyrosine kinase activity
Specific Function
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell main...
Gene Name
KIT
Uniprot ID
P10721
Uniprot Name
Mast/stem cell growth factor receptor Kit
Molecular Weight
109863.655 Da
References
  1. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR: Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res. 2007 Aug 15;13(16):4874-81. [PubMed:17699867]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H: Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol. 2011 Jan;51(1):75-83. doi: 10.1177/0091270010367428. Epub 2010 Aug 11. [PubMed:20702754]
  2. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]
  3. Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H: Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009;31 Pt 2:2459-69. doi: 10.1016/j.clinthera.2009.11.015. [PubMed:20110053]
  4. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]
  2. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Yin OQ, Gallagher N, Fischer D, Zhao L, Zhou W, Leroy E, Golor G, Schran H: Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects. Clin Drug Investig. 2011;31(3):169-79. doi: 10.2165/11538700-000000000-00000. [PubMed:21184622]
  2. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]
  2. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75. doi: 10.1016/j.clinthera.2008.11.014. [PubMed:19108785]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662]
  3. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. doi: 10.1016/j.bcp.2009.04.002. Epub 2009 Apr 11. [PubMed:19427995]
  2. Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28. [PubMed:19785662]
  3. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. doi: 10.1182/blood-2010-07-294330. Epub 2010 Sep 1. [PubMed:20810928]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
Gene Name
SLCO1B1
Uniprot ID
Q9Y6L6
Uniprot Name
Solute carrier organic anion transporter family member 1B1
Molecular Weight
76447.99 Da
References
  1. Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A: Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. Br J Cancer. 2014 Feb 18;110(4):894-8. doi: 10.1038/bjc.2013.811. Epub 2014 Jan 7. [PubMed:24398510]

Drug created on October 20, 2007 03:39 / Updated on July 16, 2018 21:23